ロード中...

A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer

Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the therapy...

詳細記述

保存先:
書誌詳細
出版年:Oncol Res
主要な著者: Fujiwara, Atsushi, Yoshida, Masamichi, Fujimoto, Hajime, Nakahara, Hiroki, Ito, Kentaro, Nishihama, Kota, Yasuma, Taro, Hataji, Osamu, Taguchi, Osamu, D’Alessandro-Gabazza, Corina N., Gabazza, Esteban C., Kobayashi, Tetsu
フォーマット: Artigo
言語:Inglês
出版事項: Cognizant Communication Corporation 2018
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7844677/
https://ncbi.nlm.nih.gov/pubmed/29321093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504018X15151523767752
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!